Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marquest Medical

This article was originally published in The Gray Sheet

Executive Summary

To receive $6.5 mil. capital infusion in exchange for granting Scherer Healthcare, Inc. the right to purchase "up to at least" 51% of Marquest's stock, according to an agreement in principle. The agreement also grants Scherer warrants to acquire approximately 1.8 mil. shares of Marquest's common stock over the next five years at prices ranging from $2-$4 per share. In addition, the two firms plan to "work together" to refinance Marquest's outstanding Swiss bond debt obligations, which are in default. Marquest plans to remain an "independently run company" that will continue having its stock traded on NASDAQ. In December, Marquest announced that it might seek protection under the U.S. Bankruptcy Code if additional financing could not be found ("The Gray Sheet" Dec. 21, p. 15)....
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000089

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel